Table 2.
Reasons and time for treatment discontinuation in patients who were treated with SGLT-2 inhibitors.
| Patients, N (%) | Months, median (IQR) | |
|---|---|---|
| Chronic or recurring genital yeast infections | 66 (67.4) | 7.5 (3-12) |
| Persistent or recurring urinary tract infections | 11 (11.2) | 6 (3-12) |
| Other adverse eventsa | 21 (21.4) | 3 (1-9) |
| Overall | 98 (100) | 6 (2-12) |
aPolyuria, nausea, hypotension, dizziness, acute coronary event, worsening of glycemic control, and rapid deterioration of renal function.